Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of <scp>HIV</scp> in a real‐world setting in Belgium-Reference-Cited by-同舟云学术

Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real‐world setting in Belgium

Published:2022-08-08 Issue:3 Volume:24 Page:267-278
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Medicine

Author:

Nasreddine Rakan¹^ORCID,Yombi Jean Cyr²,Darcis Gilles³^ORCID,Florence Eric⁴,Allard Sabine D.⁵,De Scheerder Marie‐Angélique⁶,Henrard Sophie⁷,Demeester Rémy⁸,Messiaen Peter⁹,Ausselet Nathalie¹⁰,Loeckx Matthias¹¹,Delforge Marc¹,De Wit Stéphane¹,

Affiliation:

1. Saint‐Pierre University Hospital Brussels Belgium

2. Cliniques Universitaires Saint‐Luc Brussels Belgium

3. Liège University Hospital Liège Belgium

4. Institute of Tropical Medicine Antwerp Belgium

5. Universitair Ziekenhuis Brussel Brussels Belgium

6. Ghent University Hospital Ghent Belgium

7. University Clinics of Brussels – Erasme Hospital Brussels Belgium

8. University Hospital of Charleroi Lodelinsart Belgium

9. Jessa Hospital Hasselt Belgium

10. UCL University Hospital Namur‐Godinne Yvoir Belgium

11. ViiV Healthcare Belgium

Funder

ViiV Healthcare

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hiv.13373

Reference50 articles.

1. Department of Health and Human Services.Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Accessed September 6 2021.https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/AdultandAdolescentGL.pdf

2. European AIDS Clinical Society.Guidelines version 11 October 2021. Accessed November 2 2021.https://www.eacsociety.org/files/guidelines‐10.1_finaljan2021_1.pdf

3. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

4. World Health Organization.Updated recommendations on first‐line and second‐line antiretroviral regimens and post‐exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance 2018. Accessed November 2 2021.https://www.who.int/hiv/pub/guidelines/ARV2018update/en

5. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world effectiveness and safety of switching to dolutegravir/lamivudine among people living with HIV‐1 aged over 50 years who are virologically suppressed;HIV Medicine;2024-09-06

2. Switching to Dolutegravir/Lamivudine Two-Drug Regimen: Durability and Virologic Outcomes by Age, Sex, and Race in Routine US Clinical Care;HIV/AIDS - Research and Palliative Care;2024-04

3. Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort Study;Open Forum Infectious Diseases;2024-03-18

4. Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV;HIV Medicine;2024-02-20

5. Different effects of the companion antiretroviral drugs on dolutegravir trough concentrations;AIDS;2024-01-15